The 7 most recent market catalysts affecting $IRD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 65
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13
Wedbush analyst Yun Zhong maintained an 'Outperform' rating for Opus Genetics (IRD) and raised the price target from $10 to $13. This action signals increased confidence from a pro…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 95
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
Opus Genetics (IRD) announced highly positive three- and six-month data from the low-dose cohort of its Phase 1/2 BIRD-1 trial for OPGx-BEST1, a gene therapy for BEST1-related inhe…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 85
Opus Genetics Announces Results From Low-Dose Cohort 1 Of BIRD-1, Ongoing Phase 1/2 Clinical Trial Evaluating Opgx-BEST1 Showing Favorable Safety, Tolerability Profile With No Serious Adverse Events Or Dose-Limiting Toxicities Observed
Opus Genetics reported favorable safety and efficacy data from the low-dose cohort of its Phase 1/2 BIRD-1 trial for OPGx-BEST1, a gene therapy for inherited retinal diseases. All …
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
RBC Capital's decision to lower Opus Genetics' price target from $10 to $9, while maintaining an Outperform rating, signals a recalibration of valuation expectations. This adjustme…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
Opus Genetics (IRD) reported a mixed Q2, with EPS beating estimates but sales falling significantly short. While the narrower loss might be seen positively, the substantial miss in…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 75
Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease
Opus Genetics announced the completion of patient enrollment in its registrational Phase 3 clinical trial for OPGx-LCA5, a gene therapy for LCA5-associated inherited retinal diseas…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 65
TD Cowen Initiates Coverage On Opus Genetics with Buy Rating
TD Cowen analyst Ritu Baral has initiated coverage on Opus Genetics (IRD) with a 'Buy' rating. This event is significant because new analyst coverage, especially with a positive ra…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.